Impact of metabolic syndrome on CRP levels;Importancia de los componentes del síndrome metabólico en los valores de proteína C reactiva

Revista Clinica Espanola

Volumn 206, Issue 8, 2006, Pages 363-368

  Rodilla, E ^a   Costa, J A ^a   Mares, S ^a   Miralles, A ^a   Gonzalez C ^a   Sanchez C ^a   Pascual, J M ^a  

^a HOSPITAL DE SAGUNTO   (Spain)

Author keywords

Abdominal obesity; Coronary risk; hs CRP; Metabolic syndrome

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; CREATININE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; URATE OXIDASE; UREA;

ADULT; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORONARY RISK; DIABETES MELLITUS; FEMALE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MULTIPLE REGRESSION; NEPHELOMETRY; OBESITY; OUTPATIENT; PREVALENCE; PROTEIN BLOOD LEVEL;

EID: 33749596300     PISSN: 00142565     EISSN: None     Source Type: Journal    
DOI: 10.1157/13090502     Document Type: Article

References (36)

1. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Execute Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-97.
2. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001;24:683-9.
3. Sattar N, Gaw A, Scherbakova O, Ford I, O'Reilly DS, Haffner SM, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation. 2003;108:414-9.
4. Braunwald E. Shattuck Lecture-cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. N Engl J Med. 1997; 337:1360-9.
5. Ross R. Atherosclerosis an inflammatory disease. N Engl J Med. 1999; 340:115-26.
6. Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P, et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ. 2000;321:199-204.
7. Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, et al. Air Force/Texas Coronary Atherosclerosis Prevention Study Investigators. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med. 2001;344:1959-65.
8. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation. 1998;98:731-3.
9. Mendall MA, Strachan DP, Butland BK, Ballam L, Morris J, Sweetnam PM, et al. C-reactive protein: relation to total mortality, cardiovascular mortality and cardiovascular risk factors in men. Eur Heart J. 2000;21:1584-90.
10. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347:1557-65.
11. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M, et al. Centers for Disease Control and Prevention; American Heart Association. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:499-511.
12. Petrie JC, O'Brien ET, Littler WA, de Swiet M. British Hypertension Society. Recommendations on blood pressure measurement. British Medical Journal. 1986;293:611-5.
13. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 1997;20:1183-97.
14. Friedewald WT, Levy RJ, Frederickson DS. Estimation of the concentration of low-density lipoproteins cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
15. Whicher JT, Ritchie RF, Johnson AM, Baudner S, Bienvenu J, Blirup-Jensen S, et al. New international reference preparation for proteins in human serum (RPPHS). Clin Chem. 1994;40:934-8.
16. Chobanian A, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. The JNC 7 report. JAMA. 2003;289:2560-72.
17. American Diabetes Association: Standards of Medical Care in Diabetes (Position Statement). Diabetes Care. 2004;27:S15-S35.
18. Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Moye LA, Goldman S, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol And Recurrent Events (CARE) Investigators. Circulation. 1998;98:839-44.
19. Harris TB, Ferrucci L, Tracy RP, Corti MC, Wacholder S, Ettinger WH Jr, et al. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med. 1999;106:506-12.
20. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA. 1998;279:1477-82.
21. Bassuk SS, Rifai N, Ridker PM. High-sensitivity C-reactive protein: clinical importance. Curr Probl Cardiol. 2004;29:439-43.
22. Coppack SW. Pro-inflamatory cytokines and adipose tissue. Prc Nutr Soc. 2001;60:349-56.
23. Bluher M, Fasshauer M, Tonjes A, Kratzsch J, Schon MR, Paschke R. Association of Interleukin-6, C-reactive Protein, Interleukin-10 and Adiponectin Plasma Concentrations with Measures of Obesity, Insulin Sensitivity and Glucose Metabolism. Exp Clin Endocrinol Diabetes. 2005;113(9):534-7.
24. Festa A, D'Agostino R Jr, Howard G, Mykkanen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation. 2005;102:42-7.
25. Doi Y, Kiyomara Y, Kubo M, Tanizaki Y, Okubo K, Ninomiya T, et al. Relationship Between C-Reactive Protein and Glucose Levels in Community- Dwelling Subjects Without Diabetes. The Hisayama Study. Diabetes Care. 2005;28:1211-3.
26. Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among U.S. adults. Diabetes Care. 2004;27:2444-9.
27. Balk EM, Lau J, Goudas LC, Jordan HS, Kupelnick B, Kim LU, et al. Effects of Statins on non lipid Serum Markers Associated with Cardiovascular Disease. A Systematic Review. Ann Intern Med. 2003;139:670-82.
28. Rodilla E, Gómez-Belda A, Costa JA, Aragó M, Miralles A, González C, et al. Variaciones de la proteína C reactiva con el tratamiento antihipertensivo e hipolipemiante. Med Clin (Barc). 2005;125:561-4.
29. Md Isa SH, Najihah I, Nazaimoon WM, Kamarudin NA, Umar NA, Mat NH, et al. Improvement in C-reactive protein and advanced glycosylation end-products in poorly controlled diabetics is independent of glucose control. Diabetes Res Clin Pract 2005 (revista electronica, consultado el 26-12-2005). Disponible en: http://www.sciencedirect.com/science
30. Alberti KGMM, Zimmet P, Shaw J, for the IDF Epidemiology Task Force Consensus Group. The metabolic syndrome-a new worldwide definition. Lancet. 2005;366:1059-62.
31. Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal. Diabetologia. 2005;48:1684-99.
32. Rodilla E, García L, Merino C, Costa JA, González C, Pascual JM. Importancia. del síndrome metabólico en el control de la presión arterial y de la dislipemia. Med Clin (Barc). 2004;123:601-5.
33. Ridker PM, Buring JE, Cook NR, Rifai N. C-Reactive protein, the metabolic syndrome, and risk of incidental cardiovascular events: an 8-year follow-up of 14719 initially healthy American women. Circulation. 2003;107: 391-7.
34. Miller M, Zhan M, Havas S. High attributable risk of elevated C-reactive protein level to conventional coronary heart disease risk factors: the Third National Health and Nutrition Examination Survey. Arch Intern Med. 2005;165:2063-8.
35. González C, Rodilla E, Costa JA, Justicia J, Pascual JM. Comparación entre el algoritmo de Framingham y el de SCORE en el cálculo de riesgo cardiovascular en sujetos entre 40-65 años: diferentes actitudes y distintos pacientes. Med Clin (Barc). 2006;126:527-31.
36. Gómez-Belda A, Rodilla E, Albert A, García L, González C, Pascual JM. Uso clínico de las, estatinas y objetivos terapéouticos en relación con el riesgo cardiovascular. Med Clin (Barc). 2003;121(14):527-31.